LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

30.95 0.88

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

30.51

Max

31.63

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	186
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+78.65% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	377M 2B
Ankstesnė atidarymo kaina	30.07
Ankstesnė uždarymo kaina	30.95

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-10 20:38; UTC

Uždarbis

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

2026-03-10 23:57; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-10 23:57; UTC

Rinkos pokalbiai

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

2026-03-10 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

2026-03-10 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

2026-03-10 23:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

2026-03-10 23:06; UTC

Uždarbis

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

2026-03-10 22:51; UTC

Svarbiausios naujienos

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

2026-03-10 21:39; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

2026-03-10 21:21; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

2026-03-10 21:15; UTC

Uždarbis

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

2026-03-10 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

2026-03-10 21:14; UTC

Uždarbis

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

2026-03-10 21:13; UTC

Uždarbis

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

2026-03-10 21:12; UTC

Uždarbis

Franco-Nevada 4Q Rev $597.3M >FNV

2026-03-10 21:12; UTC

Uždarbis

Franco-Nevada 4Q EPS $1.90

2026-03-10 20:57; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026-03-10 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-03-10 20:44; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026-03-10 20:34; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-03-10 20:34; UTC

Rinkos pokalbiai

Uždarbis

Oracle Building More Software for Less Money After Restructuring -- Market Talk

2026-03-10 20:23; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026-03-10 20:16; UTC

Uždarbis

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

2026-03-10 20:14; UTC

Uždarbis

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

2026-03-10 20:14; UTC

Uždarbis

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

2026-03-10 20:13; UTC

Uždarbis

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

2026-03-10 20:12; UTC

Uždarbis

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

78.65% į viršų

12 mėnesių prognozė

Vidutinis 54.9 USD 78.65%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.